Company RepliCel Life Sciences Inc. Toronto S.E.
Equities
RP
CA76027P4006
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 CAD | -.--% | -21.43% | -15.38% |
05-17 | RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04-18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
Business Summary
Number of employees: 1
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Replication Technology
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 18-12-13 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
David Kwok
DFI | Director of Finance/CFO | - | 23-08-15 |
David Hall
CHM | Chairman | 71 | 10-12-21 |
Ben Austring
COO | Chief Operating Officer | 41 | 22-11-27 |
Robert Buckler
BRD | Director/Board Member | 58 | 14-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 10-12-21 |
Peter Lewis
BRD | Director/Board Member | 69 | 11-05-26 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Robert Buckler
BRD | Director/Board Member | 58 | 14-09-30 |
Gary Boddington
BRD | Director/Board Member | 56 | 21-05-31 |
Andrew Schutte
CEO | Chief Executive Officer | 35 | 18-12-13 |
Jamie Mackay
BRD | Director/Board Member | - | 23-08-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 61,429,672 | 24,249,871 ( 39.48 %) | 0 | 39.48 % |
Company contact information
RepliCel Life Sciences, Inc.
570 Granville Street Suite 900
V6C 3P1, Vancouver
+604 248 8730
http://www.replicel.comSector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- REPCF Stock
- RP Stock
- Company RepliCel Life Sciences Inc.